Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Participants With Migraine

NCT04437199 is registered in ClinicalTrials.gov with Cerecin as lead sponsor.

NCT NCT04437199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04437199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Participants With Migraine
Lead sponsor
Cerecin
Phase
Phase 2
Overall status
Completed
Start date
December 17, 2020
Completion date
February 7, 2022
Enrollment
83 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

migraine